Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101

Inclusion Criteria:

* patients with histopathologically-documented, measurable or non measurable {evaluable}, advanced solid tumors refractory
* a life expectancy of \>3 months
* ECOG performance status score of ≤ 2 at study entry
* able to provide written informed consent.
* use of effective contraceptive measures if procreative potential exists.
* an absolute neutrophil count ≥1500/mm3
* a hemoglobin level ≥ 9gm/dL
* a platelet count ≥100,000/mm3
* a total bilirubin level ≤1.5 x the ULN
* aspartate transaminase (AST) and alanine transaminase (ALT) levels ≤2.5 x the ULN or ≤5 x the ULN if known liver metastases
* adequate renal function, as defined by a serum creatinine level ≤1.5 x the ULN.

Exclusion Criteria:

* patients with any active infection (nail bed induced fungal infections were excluded), chronic infections, and tuberculosis history.
* the females were pregnant, or lactating or showed positive urine pregnancy reaction during screening.
* patients with severe heart disease, heart failure, asthma, chronic obstructive pulmonary disease or neuropsychiatric diseases.
* uncontrolled diabetes or poor compliance with hypoglycemics;
* the presence of chronically unhealed wound or ulcers
* other chronic diseases, which, in the opinion of the investigator, could compromise safety of the patient or the integrity of study.
* newly-diagnosed or symptomatic brain metastases (patients with a history of brain metastases must have received definitive surgery or radiotherapy, be clinically stable, and not taking steroids for brain edema). Anticonvulsants are allowed.
* peritoneal carcinomatosis
* pregnancy (confirmed by serum beta human chorionic gonadotropin \[ßHCG\]) or breast-feeding (for female patients only).
* a known history or clinical evidence of a deep vein or arterial thrombosis, or pulmonary embolism
* less than six weeks from last infusion of any anti-VEGF monoclonal antibody therapy
* known history of human immunodeficiency virus infection (HIV).